GB 3010
Alternative Names: GB-3010Latest Information Update: 25 Apr 2022
At a glance
- Originator Shanghai Genechem
- Developer Shanghai Genbase Biotechnology; Shanghai Genechem
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase 0 Pancreatic cancer
Most Recent Events
- 25 Apr 2022 GB 3010 is available for licensing as of 25 Apr 2022. https://www.gcbio.com/
- 07 Sep 2021 Preclinical trials in Pancreatic cancer in China (IV, Injection) before September 2021 (NCT06054984)(Shanghai Genechem pipeline, April 2022) (Shanghai Genbase Biotechnology pipeline, April 2022)